...SILVER SPRING Md. Sept. 20 2012 /- United Therapeutics... We are thrilled to enter into this license agreement with Ascendis Ph... Pre-clinical studies in multiple animal models with a lead compound o...Under the terms of the agreement United Therapeutics will also have e...

SILVER SPRING, Md., Sept. 20, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient in Remodulin® (treprostinil) injection. United Therapeutics believes that the TransCon technology platform may enable a controlled, long-acting release of a novel, carrier-linked product, significantly enhancing the delivery profile of treprostinil by establishing a self-injectable alternative for patients who currently use the drug via a continuous infusion pump for the treatment of pulmonary arterial hypertension (PAH).

"We are thrilled to enter into this license agreement with Ascendis Pharma," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The potential to bring another novel therapeutic option to PAH patients represents an exciting new opportunity for Remodulin delivery as we constantly re-charge our mission to better the lives of patients suffering from PAH."

"Pre-clinical studies in multiple animal models with a lead compound of TransCon-linked treprostinil have already produced encouraging results, demonstrating a sustained release profile supportive of once-daily injection. The application of TransCon technology to treprostinil may also minimize injection site pain and reactions that frequently occur with continuously infused subcutaneous Remodulin," commented Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. "We are very excited to be working with Ascendis Pharma to further develop and advance this promising product into the clinic."

Under the terms of the agreement, United Therapeutics will also have exclusive rights to develop prostacycl'/>"/>

(Date:3/3/2015)... 3, 2015 Cannabis Science, Inc. (OTCQB: CBIS), a ... today announced two important developments: It launched its toll-free ... launches, and CEO Raymond C. Dabney recently ... In the article, Dabney answers questions from ... company in an industry that is too new for ...

(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/bsfm2s/cardiovascular ) has announced ... Drug Delivery - Technologies, Markets and Companies" to ... the cardiovascular system is different from delivery to other ... vascular system; it supplies blood and nutrients to all ... the vascular system for systemic effects or targeted to ...

(Date:3/3/2015)... NEW YORK , March 3, 2015 /PRNewswire/ ... a specialty pharmaceutical and medical device company focused ... of primary and metastatic liver cancers, announces that ... which completed enrollment in 2009, have been submitted ... The clinical study utilized Melphalan Hydrochloride for Injection ...

... 2011 Centre Partners Management LLC ("Centre Partners"), a leading ... and Los Angeles, today announced the completion of the sale ... Troy Limited (Nasdaq: HELE). Kaz is an international leader in ... valued at $260 million subject to certain closing working capital ...

... The MED Group, a Managed Health Care Associates, Inc. ... The website was created to help answer questions for ... about competitive bidding and how patients can receive their ... Centers for Medicare and Medicaid Services (CMS) will be ...

(Date:3/3/2015)... PLAINSBORO, N.J. (PRWEB) March 03, 2015 ... Simon Cancer Center have joined forces to share ... OncLive announced today. The collaboration is part of ... the new alliance, OncLive’s editorial and marketing teams ... a National Cancer Institute-designated cancer center, to highlight ...

(Date:3/3/2015)... The FSH Society , the ... little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today ... The purpose of the campaign is to spread awareness ... common forms of muscular dystrophies. , To begin ... FSH Society will begin sharing impactful photographs of people ...

(Date:3/3/2015)... Presale tickets for Madonna will be ready ... begin on March 9, with Madonna tour tickets expected to ... by the talented artist is a significant one for fans, ... Visit Ticketability.com to browse the inventory of Madonna ... fans to enjoy, the 2015 tour is expected to attract ...

... to extract adult stem cells from adipose or fatty ... ,International scientists will announce findings from a significant ... adipose tissue could eventually be used to treat injured ... at the third annual International Fat Applied Technology Society ...

... syndrome (also referred to as meconium aspiration) occurs when ... fluid during labor and delivery. ,Meconium is ... pregnancy and is formed from ingested amniotic fluid and ... is highly irritating to the lung when the infant ...

... California, San Diego, had discovered that a single molecule ... etc., in the body. // ,By blocking ... find a way to stave off the most common ... major cause of childhood death and disability. The researchers’ ...

... discovered a kind of immune cells called macrophages are behind ... new lymph vessels help in healing of the eyes in ... discovery of this new role for the macrophage, published in ... innovative treatments for blinding eye disease, as well as for ...

... women in the inheritance of cancer as well. A genetic mutation ... significantly increases the danger of some cancers in men according to ... examined in the familial inheritance of breast cancer among women and ... in women who have a family history of breast and ovarian ...

... The U.S. research team led by Professor Claudio Soto from ... ‘prion’ proteins behind such diseases in the blood of experimental ... Mad Cow disease, raising hopes that people could be screened ... The researchers are now refining the method to find prions ...